JP2012125257A5 - - Google Patents

Download PDF

Info

Publication number
JP2012125257A5
JP2012125257A5 JP2012077593A JP2012077593A JP2012125257A5 JP 2012125257 A5 JP2012125257 A5 JP 2012125257A5 JP 2012077593 A JP2012077593 A JP 2012077593A JP 2012077593 A JP2012077593 A JP 2012077593A JP 2012125257 A5 JP2012125257 A5 JP 2012125257A5
Authority
JP
Japan
Prior art keywords
virus
ribozyme
microorganism
composition
indicator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012077593A
Other languages
English (en)
Japanese (ja)
Other versions
JP5615865B2 (ja
JP2012125257A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012125257A publication Critical patent/JP2012125257A/ja
Publication of JP2012125257A5 publication Critical patent/JP2012125257A5/ja
Application granted granted Critical
Publication of JP5615865B2 publication Critical patent/JP5615865B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012077593A 2002-02-28 2012-03-29 外来性の物質の検出におけるリボザイムの使用 Expired - Lifetime JP5615865B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36073002P 2002-02-28 2002-02-28
US60/360,730 2002-02-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008235697A Division JP2009005712A (ja) 2002-02-28 2008-09-12 外来性の物質の検出におけるリボザイムの使用

Publications (3)

Publication Number Publication Date
JP2012125257A JP2012125257A (ja) 2012-07-05
JP2012125257A5 true JP2012125257A5 (enExample) 2013-06-20
JP5615865B2 JP5615865B2 (ja) 2014-10-29

Family

ID=27766245

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2003571491A Expired - Fee Related JP4369243B2 (ja) 2002-02-28 2003-02-26 外来性の物質の検出におけるリボザイムの使用
JP2008235697A Withdrawn JP2009005712A (ja) 2002-02-28 2008-09-12 外来性の物質の検出におけるリボザイムの使用
JP2012077593A Expired - Lifetime JP5615865B2 (ja) 2002-02-28 2012-03-29 外来性の物質の検出におけるリボザイムの使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2003571491A Expired - Fee Related JP4369243B2 (ja) 2002-02-28 2003-02-26 外来性の物質の検出におけるリボザイムの使用
JP2008235697A Withdrawn JP2009005712A (ja) 2002-02-28 2008-09-12 外来性の物質の検出におけるリボザイムの使用

Country Status (16)

Country Link
EP (2) EP1481084B1 (enExample)
JP (3) JP4369243B2 (enExample)
AR (1) AR038849A1 (enExample)
AT (1) ATE519860T1 (enExample)
AU (1) AU2003206587B2 (enExample)
BR (1) BR0307882A (enExample)
CA (1) CA2374388C (enExample)
DE (1) DE03704136T1 (enExample)
DK (1) DK1481084T3 (enExample)
ES (1) ES2241506T3 (enExample)
MX (1) MXPA04008277A (enExample)
NZ (1) NZ534488A (enExample)
TR (1) TR200501513T3 (enExample)
TW (1) TWI329132B (enExample)
WO (1) WO2003072811A2 (enExample)
ZA (1) ZA200406231B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306959C (zh) * 2004-09-21 2007-03-28 中国科学院武汉病毒研究所 草鱼呼肠孤病毒抗原亚单位疫苗制备方法
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
TW201738562A (zh) * 2009-05-28 2017-11-01 亞培生物股份有限公司 體外病原體檢驗技術

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
ATE236975T1 (de) 1992-07-02 2003-04-15 Sankyo Co Haarnadelförmiges ribozym
AU679525B2 (en) * 1992-12-04 1997-07-03 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
ES2134346T3 (es) 1993-02-16 1999-10-01 Onyx Pharma Inc Virus citopatico para el tratamiento y la profilaxis de la neoplasia.
AU699487B2 (en) 1993-04-30 1998-12-03 Robert M. Lorence Methods of treating and detecting cancer using viruses
WO1995010608A1 (en) * 1993-10-15 1995-04-20 Foundation For Research And Technology - Hellas (Fo.R.T.H.) Asymmetric hammerhead ribozymes and nucleotide sequences for their construction
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US6107027A (en) * 1994-12-14 2000-08-22 University Of Washington Ribozymes for treating hepatitis C
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
JP2001519175A (ja) 1997-10-09 2001-10-23 プロ − バイラス,インコーポレイテッド ウイルスを用いた新生物の処置
EP1066312A4 (en) 1998-03-28 2002-01-02 Univ Utah Res Found HAMMER HEAD RIBOZYMES AND THEIR DERIVATIVES AS CIRCULAR, HAIRPIN, CIRCULAR / HAIRPIN, LASSO, HAIRPIN / LASSO
AU6522599A (en) * 1998-10-23 2000-05-15 Children's Medical Center Corporation Use of a self-cleaving rna motif to modulate gene expression
AU2001251004A1 (en) * 2000-03-27 2001-10-08 Smith Kline Beecham Corporation Detection of viable agents
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Similar Documents

Publication Publication Date Title
Mishra et al. The interplay between viral-derived miRNAs and host immunity during infection
Sakai et al. The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses
Morales et al. SARS-CoV-encoded small RNAs contribute to infection-associated lung pathology
Zheng et al. Human microRNA hsa-miR-296-5p suppresses enterovirus 71 replication by targeting the viral genome
Huang et al. Establishment of a reverse genetics system for studying human bocavirus in human airway epithelia
Gao et al. The influenza A virus PB2, PA, NP, and M segments play a pivotal role during genome packaging
Noda et al. Characterization of the Ebola virus nucleoprotein–RNA complex
Devignot et al. A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus
Meyer et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
Thornburg et al. Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-κB
Sajid et al. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses
Vázquez-Calvo et al. Acid-dependent viral entry
Bradfute et al. Functional CD8+ T cell responses in lethal Ebola virus infection
Krähling et al. Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection
Zimmer et al. Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses
TR201904215T4 (tr) Bakteriyel yapay kromozomlar.
JP2012125257A5 (enExample)
Simoneau et al. Modeling multi-organ infection by SARS-CoV-2 using stem cell technology
Min et al. Mammalian adaptation in the PB2 gene of avian H5N1 influenza virus
Xue et al. Viral RNA N 6-methyladenosine modification modulates both innate and adaptive immune responses of human respiratory syncytial virus
JP2016533172A5 (enExample)
Hoffmann et al. The hemagglutinin of bat-associated influenza viruses is activated by TMPRSS2 for pH-dependent entry into bat but not human cells
Bauer et al. MicroRNAs: small but key players in viral infections and immune responses to viral pathogens
Liao et al. Host non-coding RNA regulates influenza A virus replication
Avanthay et al. NS1 and PA-X of H1N1/09 influenza virus act in a concerted manner to manipulate the innate immune response of porcine respiratory epithelial cells